Traders see an 81.5% chance that no new COVID variant of concern emerges before 2027 because SARS-CoV-2 continues to evolve within established Omicron sublineages such as XFG and BA.3.2, none of which currently meet WHO or ECDC criteria for elevated transmissibility, severity, or immune escape. BA.3.2, first detected in South Africa in late 2024 and now present in at least 23 countries with rising detections in parts of Europe through early 2026, carries notable spike-protein changes yet shows no increase in hospitalizations or overall public-health impact according to CDC and WHO assessments. Widespread prior immunity from infections and updated vaccines has kept recent strains from producing the kind of disruptive replacement event that defined earlier phases of the pandemic, supporting steady but contained circulation monitored through wastewater and genomic surveillance.